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ABSTRACT 
 
The present study was designed to determine whether Etodolac, a selective 
cyclooxygenase-2 inhibitor, prevents chemically induced intraductal papillary carcinoma (IPC) in 
the main pancreatic duct of hamsters. Hamsters were subjected to cholecystoduodenostomy with 
dissection of the distal end of the common duct. Four weeks after surgery, the surviving hamsters 
received subcutaneous injections of N-nitrosobis(2-oxopropyl)amine (BOP) 4 times at a dose of 
10 mg/kg body weight, every 2 weeks. The animals were divided into 3 groups according to the 
simultaneous oral intake of a standard pelleted diet containing Etodolac at 0% (group CE, n=30), 
0.01% (group ET, n=21), and 0.04% (group ET4, n=25), respectively. Hamsters were killed for 
pathological examination at 36 weeks after the operation. The incidence of induced pancreatic 
carcinoma was 93%, 81%, and 72% in groups CE, ET, and ET4, respectively. The pancreatic 
carcinomas were histologically classified into 4 types, i.e., tubular, papillary, and cyst 
adenocarcinoma, and IPC. The incidence of IPC and the number of IPCs per animal were 
significantly lower in groups ET4 (36% and 0.48) and ET (48% and 0.62) when compared to 
group CE (67% and 1.30). The proliferating cell nuclear antigen labeling indices in the 
noncancerous epithelial cells of the main pancreatic duct were 2.8% and 6.8% in groups ET4 and 
ET, respectively, and were significantly lower than that in group CE (10.8%). In conclusion, 
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Etodolac inhibited BOP-induced IPC in hamsters. Suppression of epithelial cell proliferation of 
the main pancreatic duct was considered as a possible mechanism of cancer prevention in this 
hamster model. 
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INTRODUCTION 
 
Intraductal papillary mucinous neoplasm (IPMN) of the pancreas, which is characterized by 
the papillary proliferation of neoplastic epithelium with mucin-hypersecretion (1), has been a 
well-established clinical and pathological entity since Ohashi et al. first described it in 1982 (2). 
The recorded incidence of this unique pancreatic disorder has been gradually increasing in 
accordance with the recent advances in diagnostic imaging modalities. An ordinary pancreatic 
ductal carcinoma derives from the pancreatic ductules, while IPMN arises from the main 
pancreatic duct or its major branches (1,3), being classified grossly into 2 types, i.e., main-duct 
IPMN and branch-duct IPMN (4). In addition, IPMNs show a wide spectrum of histological 
differentiation, ranging from benign to malignant with the hyperplasia-adenoma-carcinoma 
sequence (5-7), and can often be multifocal. Therefore, the appropriate management for IPMN 
remains unclear. Some patients with IPMN indeed require aggressive surgery such as total 
pancreatectomy, whereas some patients can be managed with limited pancreatic resections as well 
as careful observation without surgery. The advantage of a surgical approach must be balanced 
against the surgical risk and the postoperative poor quality of life with pancreatic endocrine and 
exocrine deficiency, especially in elderly patients. In the management of IPMN, therefore, a potent 
chemopreventive agent would be beneficial for patients.  
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Nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 (COX-2) 
inhibitors, have been expected to function as chemopreventive drugs against several carcinomas 
(8,9). Kokawa et al. (5), however, have recently demonstrated the incidence of COX-2 expression 
as 58% and 70% in intraductal papillary mucinous adenoma (IPMA) and carcinoma (IPMC) of the 
pancreas, respectively. It has been described that the incidence of COX-2 expression arises in 
accordance with the progression of the adenoma-carcinoma sequence in IPMNs (6,7). These 
findings suggest that the suppression of COX-2 expression can prevent the development and 
progression of IPMN. In the present study, we investigated the effects of Etodolac, a selective 
COX-2 inhibitor, on the prevention of IPMNs of the pancreas by using a hamster model in which 
intraductal papillary carcinoma (IPC) could be induced in the main pancreatic duct or its major 
branches (10). We used Syrian hamsters as the animal model because the anatomical structure of 
their pancreaticobiliary ductal system, bile acid composition, and pancreatic juice components in 
this species are similar to those of humans (11,12). 
 
MATERIALS AND METHODS   
 
Animals 
A total of 76, 7-week-old female Syrian golden hamsters (Shizuoka Laboratory Animal 
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Center, Shizuoka, Japan) were used. The average weight of hamsters at the time of initiation of the 
experiments was 100 g. Animals were housed one per cage with sawdust bedding under standard 
laboratory conditions in the Laboratory Animal Center for Biochemical Research at Nagasaki 
University Graduate School of Biomedical Sciences. The animals were checked daily and 
weighed weekly throughout the experimental period. All experiments were performed following 
the Guidelines for Animal Experimentation of Nagasaki University Graduate School of 
Biomedical Sciences. 
Surgical techniques  
Following intraperitoneal administration of sodium pentobarbital (50 mg/kg body weight), 
hamsters were subjected to cholecystoduodenostomy with dissection of the distal end of the 
common duct, so that bile would regurgitate into the pancreatic ducts and activate the epithelial 
cell kinetics of the main pancreatic duct (10).  
Experimental protocol 
All hamsters received four biweekly subcutaneous injections of 
N-nitrosobis(2-oxopropyl)amine (BOP) (Nakarai Chemical Co., Kyoto, Japan), started 4 weeks 
after surgery, at a dose of 10 mg/kg body weight. The animals were divided into 3 groups 
according to the simultaneous oral intake of a CE-2 pelleted diet (Clea Japan, Tokyo, Japan), 
which contained 0% (group CE), 0.01% (group ET), and 0.04% Etodolac (group ET4), 
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respectively. The dosage of 0.01% Etodolac in the CE-2 pelleted diet was determined by 
calculating the daily amount of diet ingestion of hamsters and considering the clinical daily-dose 
of Etodolac in humans. The body weight and amount of diet ingestion in each animal was checked 
weekly throughout the experiment. Hamsters were killed for pathological investigations at 36 
weeks after surgery. At autopsy, pancreatic tissue samples were taken from the distal portion of the 
splenic lobe of the pancreas, frozen immediately in liquid nitrogen, and stored at -80oC in a sterile 
1.5-ml Eppendolf tube for the analysis of prostaglandin products. The residual pancreas was 
embedded in paraffin and processed routinely for hematoxylin and eosin staining and then 
examined by a pathologist who was blinded to the treatment allocation of the study. For the 
investigation of adverse effects of Etodolac such as gastric ulceration and myocardial injury, the 
stomach and the heart were investigated by means of macroscopic and microscopic examination. 
Tumor lesions induced in the pancreas were classified on the basis of the WHO classification of 
tumors of the hamster (13). 
Prostaglandin measurement 
To assess the suppressive effects of Etodolac on COX-2 activity, the prostaglandin E2 
(PGE2) products in the pancreatic tissues were measured. The frozen tissue obtained from the 
splenic lobe of the pancreas was homogenized in saline containing 10 mg/l indomethacin, and 
ethanol was added to achieve the final proportion of 20%. After centrifugation, the supernatant 
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was removed and agitated in the octadecylsilyl silica (FUJIGEL HANBAI Co. Ltd., Tokyo, Japan) 
suspension to absorb PGE2. Deproteinization and delipidization were performed, and 
prostaglandins were eluted by ethyl acetate. The dried residue containing prostaglandins was 
dissolved in eluent 1 (acetonitrile: chloroform: acetic acid, 10:90:0.5) and applied to a silica open 
minicolumn Bond Elut Si (Varian, Inc. Scientific Instruments, CA, USA). The column was 
washed with 10 ml eluent 1, after which PGE2 was eluted first with 5 ml eluent 2 (acetonitrile: 
chloroform: acetic acid, 20:80:0.5) and then 5 ml eluent 3 (acetonitrile: chloroform: acetic acid, 
50:50:0.5). We assayed PGE2 by a radioimmunoassay technique using a [125 I] Prostaglandin E2 
RIA kit NEK-020 (PerkinElmer Life And Analytical Sciences, Inc., MA, USA).   
Cell kinetic studies 
Proliferating cell nuclear antigen (PCNA) was used for evaluation of the epithelial cell 
kinetic activity of the main pancreatic duct. Pancreatic tissue sections obtained from all hamsters 
were cut at 4 μm, mounted on glass slides coated with 5-aminoprophyltriethoxy saline, and 
dewaxed in xylene. The sections were treated with microwave heating for 5 min in 
phosphate-buffered saline at 500W. After blocking of endogenous peroxidase, the sections were 
incubated with mouse monoclonal antibodies against PCNA (clone-PC 10; DAKO, Kyoto, Japan) 
at a dilution of 1:100. The cell nuclei were counterstained with hematoxylin. The proportion of 
labeled nuclei (labeling index; LI) was determined by counting the labeled nuclei in >1,000 
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normal epithelial cells of the main pancreatic duct. We examined 19, 16, and 26 regions of normal 
epithelium in the main pancreatic duct in groups CE, ET, and ET4 respectively.  
Statistical analysis 
The Mann-Whitney U-test was used for statistical analysis. Differences of p<0.05 were 




 The number of hamsters examined was 30, 21, and 25 in groups CE, ET, and ET4, 
respectively. The difference in the number of hamsters in each group was mainly due to the 
operative death within 4 weeks after surgery. 
Transition of body weight and amount of diet ingestion 
            The transition curves of the average body weight and amount of diet ingestion in each 
hamster group during the experiment are shown in Fig. 1. There were no statistically differences in 
either body weight or diet ingestion between the 3 groups in any period. In addition, no hamsters 
showed either gastric ulcer or myocardial injury with regard to either macroscopic or microscopic 
aspects. 
The amount of Etodolac administration in hamsters 
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          The amount of Etodolac administration in hamsters, calculated on the basis of diet ingestion, 
was 36 to 53 mg/kg body weight/week in group ET and 160 to 192 mg/kg body weight/week in 
group ET4, respectively (Fig. 2). In group ET, the amount of Etodolac intake was within the 
human clinical dosage (i.e., 28 to 56 mg/kg body weight/week). 
Prostaglandin products 
The mean PGE2 production in the pancreatic tissue was 19.7±13.3 (mean±SD), 15.4±13.3, 
and 10.2±7.8 pg/wet weight mg in groups CE, ET, and ET4, respectively, with production 
decreasing in proportion to the mixing dosage of Etodolac with a statistically significant difference 
between groups CE and ET4 (p<0.01) (Fig. 3).  
Carcinogenic studies  
The incidence, number, and histological findings of pancreatic carcinomas induced in 
hamsters are summarized in Table I. Pancreatic carcinomas developed in 93%, 81%, and 72% of 
hamsters in groups CE, ET, and ET4, respectively. The difference was statistically significant 
between groups CE and ET4 (p<0.05). The induced pancreatic tumors were classified grossly into 
4 types histologically: tubular, papillary and cystic adenocarcinoma, and IPC arising in the main 
pancreatic duct. Although some IPCs were recognized in the first-order pancreatic branches, these 
lesions were not counted in this study since they could not be distinguished from the IPC 
originating in the main pancreatic duct. The majority of induced pancreatic carcinomas were 
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tubular adenocarcinomas in each group. However, numerous IPCs were recognized in the main 
pancreatic duct in hamsters of group CE (Fig. 4).  The incidences of IPC were 67%, 48%, and 36% 
in groups CE, ET, and ET4, respectively, and were significantly lower in group ET4 (p<0.05) 
when compared to group CE. The number of IPCs per animal was 1.30, 0.62, and 0.48 in groups 
CE, ET, and ET4, respectively, and was significantly fewer in groups ET (p<0.05) and ET4 
(p<0.01) when compared to group CE. Both the incidence and number of tubular adenocarcinomas 
were not affected by the Etodolac treatment.   
Cell kinetic studies  
            The PCNA-LIs of normal epithelial cells of the main pancreatic duct were 10.8±4.9% 
(mean±SD), 6.8±3.8%, and 2.8±2.5% in groups CE, ET, and ET4, respectively. All of the 
differences between groups were statistically significant (Fig. 5). 
 
DISCUSSION 
    
Recent clinical investigations have revealed the presence of COX-2 expression in a variety 
of cancers of the colon, lung, stomach, and esophagus (14-16). The over expression of COX-2 
inhibits the apoptosis of cancer cells (17), resulting in prolonged survival of DNA-damaged cells, 
increases in metastatic potential (18), or promotion of angiogenesis (19). Therefore, selective 
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COX-2 inhibitors have been proposed to be an appropriate chemopreventive drug against cancer. 
In fact, the chemopreventive effects of selective COX-2 inhibitors have been demonstrated in 
pancreatic cancer cell lines (20,21) and animal models (22,23) because COX-2 expression is also 
involved in the development and progression of invasive ductal carcinoma of the pancreas (24,25). 
However, controversy remains regarding the usefulness of chemoprevention against pancreatic 
cancer (26), and El-Rayes et al. (27) have recently reported that a selective COX-2 inhibitor 
(celecoxib) alone might be insufficient to reverse the chemoresistance in pancreatic cancer in a 
clinical study of simultaneous use of gemcitabine. In contrast, Crowell et al. (24) have advocated 
that COX-2 activation is extremely important in the early stages of human pancreatic 
carcinogenesis; namely, in PanIN1 and PanIN2 lesions. In addition, the significance of COX-2 
expression at an early stage of polyp formation in the intestine has been reported (28). Because 
IPMNs of the pancreas show the hyperplasia-adenoma-carcinoma sequence (5-7) and have less 
aggressive behavior compared to ordinary pancreatic ductal carcinoma (29), selective COX-2 
inhibitor might be a potential drug for the prevention of IPMNs.    
In the present study, the oral administration of Etodolac had no chemopreventive effects on 
the development of BOP-induced tubular adenocarcinoma of the pancreas, which is the ordinary 
type of human pancreatic cancer. However, Etodolac inhibited the occurrence of IPCs in the main 
pancreatic duct even in the hamsters of group ET, in which the Etodolac administration to 
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hamsters was equal to the human clinical dosage. To the best of our knowledge, this is the first 
successful in vivo study of the chemoprevention of IPCs of the pancreas by means of a selective 
COX-2 inhibitor. Both the PGE2 production in the pancreas tissue and PCNA-LIs of noncancerous 
epithelial cells of the main pancreatic duct were suppressed in proportion to the administrating 
dosage of Etodolac in this study. It is well known that COX mediates the late limiting step of 
prostaglandin biosynthesis in the arachidonic acid cascade and that PGE2 is a reliable biomarker of 
COX activity (24,30). Thus, the present results indicate that suppression of epithelial cell 
proliferation of the main pancreatic duct through the reduction of PGE2 production in the pancreas 
by Etodolac is a possible mechanism of cancer prevention in our hamster model.  
IPCs induced in the main pancreatic duct of our hamster model produced a smaller amount 
of mucin when compared to IPMNs in humans. However, there were many similarities between 
IPCs and IPMNs from an oncological perspective, i.e., the tumor development from the main or 
large pancreatic ducts, intraductal papillary growth with a histological pattern of papillary 
proliferation of tumor cells, and low-grade malignancy (10,29). In addition, no hamsters showed 
any adverse effects of Etodolac on the stomach and the heart, even in hamsters of the ET groups, 
although cardiovascular morbidity remains a clinical concern with long-term use of selective 
COX-2 inhibitors. These findings may also support the idea that Etodolac could be a safe and 
useful drug for the prevention of IPMNs in humans. In particular, branch duct IPMNs without 
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clinico-radiological parameters indicative of possible malignancy in younger patients and/or 
IPMNs in the elderly with a high risk for surgery are good subjects for cancer chemoprevention. In 
multifocal branch duct IPMNs, surgical removal of the prominent lesions and a close observation 
of the remaining lesions in the remnant pancreas with chemoprevention by means of selective 
COX-2 inhibitors may be a reasonable treatment.  
In conclusion, the present study has demonstrated the chemopreventive effects of 
Etodolac on BOP-induced intraductal papillary carcinoma of the main pancreatic duct in hamsters. 
Because human IPMNs have many characteristic features suited for cancer chemoprevention, the 
administration of selective COX-2 inhibitors may be a good adaptation to control IPMNs or to 
prevent IPMN recurrence after surgery. 
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FIGURE LEGENDS 
Figure 1  Transition curves of average body weight and the amount of diet ingestion of 
hamsters in each group during the experiment. Solid line, the average body weight of 
hamsters; dashed line, average amount of diet ingestion.  
Figure 2     The weekly amount of Etodolac administration to hamsters in groups ET and ET4 that 
was calculated on the basis of diet ingestion containing Etodolac. The gray area 
shows the range of the usual clinical dosage of Etodolac. In group ET, Etodolac 
administration levels were within human clinical dosage levels throughout the 
experiment.  
Figure 3     The mean PGE2 production per wet weight of the pancreas tissue in each group. PGE2 
production in the pancreas tissue was decreased in proportion to the mixing dosage of 
Etodolac. 
Figure 4    Representative case of IPC of the main pancreatic duct induced in hamsters. IPC shows 
a marked papillary proliferation growing into the lumen of the main pancreatic duct 
(H&E ×150). 
Figure 5    PCNA-LIs of normal epithelial cells of the main pancreatic duct of hamsters in each 
group. PCNA-LIs were suppressed in accordance with the mixing dosage of Etodolac 
with statistical significance. 
- 21 - 












- 22 - 












- 23 - 












- 24 - 












- 25 - 
                                                        
 
